Investing.com - (NYSE:Pfizer) fourth-quarter earnings missed estimates as sales were in line.
Pfizer reported an 11% YoY fall in adjusted, diluted Q4 EPS to $0.47 against an estimate of $0.50.
Revenues were down 3% at $13.63, compared with a forecast of $13.61 bn.
The U.S. drug maker attributed the YoY decline in revenues to fewer selling dates than a year earlier.
Full-year EPS was up 9% at $2.40 as revenues rose 8% to $52.82 bn.